IL274488B2 - Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide - Google Patents

Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Info

Publication number
IL274488B2
IL274488B2 IL274488A IL27448820A IL274488B2 IL 274488 B2 IL274488 B2 IL 274488B2 IL 274488 A IL274488 A IL 274488A IL 27448820 A IL27448820 A IL 27448820A IL 274488 B2 IL274488 B2 IL 274488B2
Authority
IL
Israel
Prior art keywords
crystalline form
composition
treating
thalassemia
angles
Prior art date
Application number
IL274488A
Other languages
English (en)
Hebrew (he)
Other versions
IL274488A (en
IL274488B1 (en
Original Assignee
Agios Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=64734113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL274488(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Agios Pharmaceuticals Inc filed Critical Agios Pharmaceuticals Inc
Publication of IL274488A publication Critical patent/IL274488A/en
Publication of IL274488B1 publication Critical patent/IL274488B1/en
Publication of IL274488B2 publication Critical patent/IL274488B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL274488A 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide IL274488B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762589822P 2017-11-22 2017-11-22
US201862691709P 2018-06-29 2018-06-29
PCT/US2018/062197 WO2019104134A1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Publications (3)

Publication Number Publication Date
IL274488A IL274488A (en) 2020-06-30
IL274488B1 IL274488B1 (en) 2023-09-01
IL274488B2 true IL274488B2 (en) 2024-01-01

Family

ID=64734113

Family Applications (3)

Application Number Title Priority Date Filing Date
IL305343A IL305343B1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
IL274488A IL274488B2 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
IL322576A IL322576A (en) 2017-11-22 2018-11-21 Crystalline forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IL305343A IL305343B1 (en) 2017-11-22 2018-11-21 Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL322576A IL322576A (en) 2017-11-22 2018-11-21 Crystalline forms of N-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide

Country Status (27)

Country Link
US (2) US11254652B2 (enExample)
EP (2) EP3713919B1 (enExample)
JP (2) JP7275130B2 (enExample)
KR (3) KR20250034202A (enExample)
CN (2) CN117551030A (enExample)
AU (2) AU2018373122B2 (enExample)
BR (1) BR112020010185A2 (enExample)
CA (1) CA3081945A1 (enExample)
DK (1) DK3713919T3 (enExample)
ES (1) ES2959764T3 (enExample)
FI (1) FI3713919T3 (enExample)
HR (1) HRP20230931T1 (enExample)
HU (1) HUE063264T2 (enExample)
IL (3) IL305343B1 (enExample)
LT (1) LT3713919T (enExample)
MD (1) MD3713919T2 (enExample)
MX (2) MX2020005348A (enExample)
PH (1) PH12020550644A1 (enExample)
PL (1) PL3713919T3 (enExample)
PT (1) PT3713919T (enExample)
RS (1) RS64592B1 (enExample)
SG (1) SG11202004587XA (enExample)
SI (1) SI3713919T1 (enExample)
SM (1) SMT202300327T1 (enExample)
TW (2) TW202334115A (enExample)
UA (1) UA127502C2 (enExample)
WO (1) WO2019104134A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2448582T (pt) * 2009-06-29 2017-07-10 Agios Pharmaceuticals Inc Compostos e composições terapêuticas
US11014927B2 (en) 2017-03-20 2021-05-25 Forma Therapeutics, Inc. Pyrrolopyrrole compositions as pyruvate kinase (PKR) activators
ES2989438T3 (es) 2018-09-19 2024-11-26 Novo Nordisk Healthcare Ag Activación de la piruvato cinasa R
US12053458B2 (en) 2018-09-19 2024-08-06 Novo Nordisk Health Care Ag Treating sickle cell disease with a pyruvate kinase R activating compound
EP3972957A1 (en) * 2019-05-22 2022-03-30 Agios Pharmaceuticals, Inc. Crystalline salt forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
US11878049B1 (en) * 2019-06-14 2024-01-23 Agios Pharmaceuticals, Inc. Mitapivat therapy and modulators of cytochrome P450
EP4031132A4 (en) 2019-09-19 2023-09-13 Forma Therapeutics, Inc. Activating pyruvate kinase r
EP4097085A1 (en) 2020-01-28 2022-12-07 Teva Pharmaceuticals International GmbH Solid state forms of mitapivat and process for preparation thereof
EP4216956A1 (en) * 2020-09-25 2023-08-02 Agios Pharmaceuticals, Inc. Pharmaceutical formulation
CN116568281A (zh) * 2020-09-25 2023-08-08 安吉奥斯医药品有限公司 药物制剂
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
WO2023154036A1 (en) 2022-02-08 2023-08-17 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat
WO2022231627A1 (en) 2021-04-30 2022-11-03 Agios Pharmaceuticals, Inc. Methods for titrating mitapivat for use in treating thalassemia
JP2024518779A (ja) 2021-04-30 2024-05-02 アジオス ファーマシューティカルズ， インコーポレイテッド ミタピバットを滴定するための方法
EP4147700A1 (en) * 2021-09-08 2023-03-15 LQT Therapeutics Inc. N-(4-(azaindazol-6-yl)-phenyl)-sulfonamides for use in the treatment of sickle cell disease
EP4433057A1 (en) 2021-11-16 2024-09-25 Agios Pharmaceuticals, Inc. Compounds for treating mds-associated anemias and other conditions
WO2024084501A1 (en) 2022-10-17 2024-04-25 Mylan Laboratories Limited Crystalline polymorphs of mitapivat and mitapivat hemisulfate
ES2975743A1 (es) * 2022-11-22 2024-07-12 Moehs Iberica Sl Metodo de preparacion de mitapivat, intermedios de sintesis de mitapivat y metodos de preparacion de los mismos
WO2024228131A1 (en) * 2023-05-02 2024-11-07 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of 8-quinoline sulfonamide, n-[4-[[4(cyclopropylmethyl)-1-piperazinyl] carbonyl] phenyl]-sulfate and its process for preparation thereof
WO2025008787A1 (en) * 2023-07-05 2025-01-09 Biophore India Pharmaceuticals Pvt. Ltd Solid forms of mitapivat hemisulfate
WO2025083627A1 (en) * 2023-10-18 2025-04-24 Apitoria Pharma Private Limited Novel crystalline forms of mitapivat sulfate and processes for preparation
WO2025146636A1 (en) * 2024-01-03 2025-07-10 Tianish Laboratories Private Limited Novel crystalline polymorphs of mitapivat sulfate salt

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785450B2 (en) * 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN191496B (enExample) 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
GB2383042A (en) 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
CN108451955B (zh) 2011-05-03 2022-02-01 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
US20140249150A1 (en) 2011-10-13 2014-09-04 Agios Pharmaceuticals, Inc Activators of pyruvate kinase m2 and methods of treating disease
WO2014018851A1 (en) * 2012-07-26 2014-01-30 Joslin Diabetes Center, Inc. Predicting and treating diabetic complications
IN2015DN01662A (enExample) 2012-09-18 2015-07-03 Auspex Pharmaceuticals Inc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8785450B2 (en) * 2009-06-29 2014-07-22 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2016201227A1 (en) * 2015-06-11 2016-12-15 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGE ET AL.,, PHARMACEUTICALS SALTS, 1 January 1977 (1977-01-01) *
BYRN ET AL.,, PHARMACEUTICAL SOLIDS: A STRATEGIC APPROACH TO REGULATORY CONSIDERATIONS, 1 January 1995 (1995-01-01) *
CAIRA,, CRYSTALLINE POLYMORPHISM OF ORGANIC COMPOUNDS, 1 January 1998 (1998-01-01) *

Also Published As

Publication number Publication date
UA127502C2 (uk) 2023-09-13
AU2024200724A1 (en) 2024-02-22
IL274488A (en) 2020-06-30
CN111372920A (zh) 2020-07-03
SMT202300327T1 (it) 2023-11-13
ES2959764T3 (es) 2024-02-28
MX2022009998A (es) 2022-09-19
JP2021504338A (ja) 2021-02-15
MX2020005348A (es) 2020-08-13
EP4285904A3 (en) 2023-12-20
JP2023093762A (ja) 2023-07-04
EP3713919A1 (en) 2020-09-30
KR20250034202A (ko) 2025-03-10
CN111372920B (zh) 2023-10-20
IL274488B1 (en) 2023-09-01
EP3713919B1 (en) 2023-08-02
BR112020010185A2 (pt) 2021-01-12
KR20240108581A (ko) 2024-07-09
PT3713919T (pt) 2023-10-26
IL305343A (en) 2023-10-01
HUE063264T2 (hu) 2024-01-28
KR102682430B1 (ko) 2024-07-08
JP7275130B2 (ja) 2023-05-17
SG11202004587XA (en) 2020-06-29
PH12020550644A1 (en) 2021-04-26
MD3713919T2 (ro) 2024-02-29
AU2018373122B2 (en) 2023-11-09
TW202334115A (zh) 2023-09-01
IL322576A (en) 2025-10-01
RS64592B1 (sr) 2023-10-31
KR102777452B1 (ko) 2025-03-10
DK3713919T3 (da) 2023-09-25
PL3713919T3 (pl) 2023-12-27
KR20200090787A (ko) 2020-07-29
CA3081945A1 (en) 2019-05-31
EP4285904A2 (en) 2023-12-06
AU2018373122A1 (en) 2020-05-21
US20220220093A1 (en) 2022-07-14
SI3713919T1 (sl) 2023-10-30
TWI808108B (zh) 2023-07-11
TW201930289A (zh) 2019-08-01
FI3713919T3 (fi) 2023-09-29
WO2019104134A1 (en) 2019-05-31
CN117551030A (zh) 2024-02-13
HRP20230931T1 (hr) 2023-11-24
LT3713919T (lt) 2023-10-10
US20200277279A1 (en) 2020-09-03
US11254652B2 (en) 2022-02-22
IL305343B1 (en) 2025-09-01

Similar Documents

Publication Publication Date Title
IL274488B2 (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl) piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
JP2021504338A5 (enExample)
WO2008144730A3 (en) Stable pharmaceutical formulation for a dpp-iv inhibitor
JPWO2019104134A5 (enExample)
FI3307271T3 (fi) Pyruvaattikinaasin aktivaattorien käyttämisen menetelmä
FI3470063T3 (fi) Lääkekoostumuksia cftr-välitteisten sairauksien hoitoon
ES2910003T3 (es) Compuestos y composiciones de cocristal iónico de litio de anión orgánico
RU2008113439A (ru) Композиции с замедленным высвобождением лекарственного средства
JP2020532535A5 (enExample)
RU2015106137A (ru) Кристаллический полиморф 4-[5-(пиридин-4-ил)-1н-1,2,4-триазол-3-ил]-пиридин-2-карбонитрила и способ его получения
KR20090019914A (ko) 테가세로드를 단독으로 포함하거나 또는 양성자 펌프 억제제와 조합으로 포함하는, 위 손상의 치료 또는 예방용 조성물
JP2016530238A5 (enExample)
JP2011527687A5 (enExample)
JP2006104184A (ja) ストロンチウムラネレートのアルファー（α）−結晶形、その製造方法、及びそれを含む医薬組成物
RU2016106336A (ru) Противотуберкулезная композиция, содержащая рифампицин, изониазид, этамбутол и пиразинамид, и способ ее получения
HRP20250002T1 (hr) Ampreloksetin, namijenjen upotrebi u liječenju neurogene ortostatske hipotenzije
RU2009124593A (ru) Полиморфные формы деферасирокса (icl670a)
JP2024045113A5 (enExample)
CA2728890C (en) Amide derivative-containing pharmaceutical composition
NZ805778A (en) Crystalline forms of n-(4-(4-(cyclopropylmethyl)piperazine-1- carbonyl)phenyl)quinoline-8-sulfonamide
WO2013169218A1 (en) Pharmaceutical compositions of s-etodolac
TR201723035A2 (tr) Geciktirilmiş salınımlı deksketoprofen bileşimi.
JP2019530719A5 (enExample)
JP2018065752A (ja) シロドシン含有医薬組成物とその製造方法
JP2012097034A5 (enExample)